Citizens Reiterates Cidara Therapeutics (CDTX) at Market Outperform After CD388 Phase 2 Trial
Tweet Send to a Friend
Citizens analyst Roy Buchanan reiterated a Market Outperform rating and $173.00 price target on Cidara Therapeutics (NASDAQ: CDTX).The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
